List view / Grid view
23 September 2014 | By ImmuSmol
ImmuSmol is announcing it has raised 500 000 euros to progress its cancer immunotherapy program to in vivo proof-of-concept...
23 September 2014 | By GlobalData
Eli Lilly’s recent partnership with AstraZeneca to develop oral beta-secretase cleaving enzyme (BACE) inhibitor AZD3293 for Alzheimer’s Disease (AD) is a positive step forward for this challenging treatment market, says an analyst with research and consulting firm GlobalData...
23 September 2014 | By Hummingbird IRB
Hummingbird IRB has received full accreditation from the Association for the Accreditation of Human Research Protection Programs, Inc...
23 September 2014 | By Codexis
Codexis, Inc. announced the appointment of Kathleen Sereda Glaub to its board of directors...
23 September 2014 | By Andrew Lloyd & Associates
A new antigens formulation against pandemic flu (A H1N1 virus) proved six times more effective than other vaccines...
23 September 2014 | By The Institute of Cancer Research
Even long stretches of DNA that contain no genes at all can affect the risk of breast cancer, by physically interacting with genes elsewhere, a new study reports...
23 September 2014 | By Horizon Discovery
Horizon Discovery Group plc announces its interim results for the six months ended 30 June 2014...
22 September 2014 | By Children’s Cancer Institute and Abcam plc
Compounds allow further exploration of MRP4 function and have potential in cancer therapeutic development...
22 September 2014 | By Domain Therapeutics
The world-renowned GPCR specialist will assemble a team of experts in drug discovery and development to guide Domain’s programs...
22 September 2014 | By kdm communications
Innovative batch and flow reactors from leading manufacturer Syrris are proving advantageous for a variety of nanoparticle applications, offering scientists working in the field numerous benefits...
CEVEC Pharmaceuticals, the developer and licensor of the CAP Technology, today announced its new management team.
22 September 2014 | By Kymab
Kymab Limited announced that the European Patent Office has granted Kymab's request to entirely revoke European Patent EP1,360,287B1, owned by Regeneron Pharmaceuticals Inc...
22 September 2014 | By Andrew Lloyd & Associates
GENTICEL announces that following the Supervisory Board’s meeting held on September 11, 2014, Mary Tanner has been appointed to the board as a new independently-acting member and as Audit Committee chairman...
22 September 2014 | By Gilead Sciences
Gilead Sciences, Inc. announced that the European Commission has granted marketing authorization for Zydelig® (idelalisib), 150 mg tablets, a first-in-class oral treatment for two incurable blood cancers - chronic lymphocytic leukemia and follicular lymphoma...
19 September 2014 | By Nexstim
Nexstim Oy announces its intention to proceed with an Initial Public Offering of Nexstim on NASDAQ OMX First North Finland and NASDAQ OMX First North Sweden...
